Get the Stockscreener App
14.98
3.00%
-0.4635
Lb Pharmaceuticals Inc stock is traded at $14.98, with a volume of 2,024.
It is down -3.00% in the last 24 hours and up +0.00% over the past month.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
See More
Previous Close:
$15.44
Open:
$15.59
24h Volume:
2,024
Relative Volume:
0.03
Market Cap:
$313.93M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.08%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$15.17
$15.61
1-Week Range:
$14.85
$16.30
52-Week Range:
$13.36
$17.50
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Compare LBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
15.61 | 346.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
Analysts Set LB Pharmaceuticals Inc (NASDAQ:LBRX) PT at $30.50 - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Raised to Hold at Zacks Research - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Biopharma financings climb to $18.7B in the third quarter - BioWorld MedTech
Q3 Earnings Forecast for LBRX Issued By Leerink Partnrs - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Leerink Partnrs - Defense World
September biopharma financings jump 54% to $7.12B - BioWorld MedTech
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded at Leerink Partnrs - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Coverage Initiated by Analysts at Leerink Partners - Defense World
Drug developer MapLight eyes $704.3 million valuation in US IPO - Reuters
LB Pharmaceuticals to Present Three Posters at 38th ECNP - GlobeNewswire
Leerink Partners Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $34 - 富途牛牛
Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential - TipRanks
Leerink Partners Initiates LB Pharmaceuticals at Outperform With $34 Price Target - MarketScreener
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms - The Manila Times
0.66 effect size in cognition: LB Pharma's LB‑102 shows dose‑dependent gains; 3 ECNP posters Oct 11-14 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Now Covered by Analysts at Leerink Partners - MarketBeat
LB Pharmaceuticals stock initiated at Outperform by Leerink Partners - Investing.com
Promising Prospects for LB Pharmaceuticals: Buy Rating Affirmed on LB-102’s Market Potential - TipRanks
Piper Sandler initiates coverage on LB Pharmaceuticals stock with Overweight rating - Investing.com
Stifel initiates coverage on LB Pharmaceuticals stock with Buy rating - Investing.com
LB Pharmaceuticals IncCommon Stock (Nasdaq:LBRX) Stock Quote - FinancialContent
LB Pharmaceuticals Appoints William Kane and Rekha Hemrajani To Board - citybiz
LB Pharmaceuticals adds two directors following Nasdaq debut By Investing.com - Investing.com Nigeria
LB Pharmaceuticals adds two directors following Nasdaq debut - Investing.com India
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - The Manila Times
Strategic Board Expansion: LB Pharmaceuticals Strengthens Leadership for Phase 3 Schizophrenia Drug Trial - Stock Titan
Scoop: Voltron Therapeutics plans IPO next year - Axios
Deep Track Capital, LP Acquires Significant Stake in LB Pharmaceuticals Inc - GuruFocus
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pha - GuruFocus
COMMODORE CAPITAL LP Acquires 1,225,000 Shares in LB Pharmaceuti - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in LB Pharmace - GuruFocus
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Big Pharma-backed MapLight plots IPO to advance neuro pipeline - Fierce Biotech
Novo-Backed Drug Developer MapLight Therapeutics Files for IPO - Bloomberg.com
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
Layoff Tracker: Arsenal, X4 Lay Off Half of Staff to Cut Costs - BioSpace
Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Warren Buffett, Steve Cohen, Mario Gabelli, Balyasny Asset Management, LB Pharmaceuticals Inc (LBRX), Avista Corp (AVA), and More - Insider Monkey
Schizophrenia drug developer LB Pharma jumps in trading debut - MSN
Wednesday 9/17 Insider Buying Report: LBRX, RAPP - Nasdaq
Major Investors Make Bold Moves in LB Pharmaceuticals Stock! - TipRanks
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Launches $285 Million Initial Public Offering - Global Legal Chronicle
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) - Investing.com
Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US - insights.citeline.com
U.S. IPO Weekly Recap: Klarna Leads Busiest Week For IPOs Since 2021, As More Names Join The Pipeline - Seeking Alpha
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
There is no financial data for Lb Pharmaceuticals Inc (LBRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Lb Pharmaceuticals Inc Stock (LBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):